Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

GRPR

  • Open Access
    Substitution of L-Trp by α-methyl-L-Trp in 177Lu-RM2 results in 177Lu-AMTG, a high affinity GRPR ligand with improved in vivo stability
    Thomas Guenther, Sandra Deiser, Veronika Felber, Roswitha Beck and Hans-Juergen Wester
    Journal of Nuclear Medicine January 13, 2022, jnumed.121.263323; DOI: https://doi.org/10.2967/jnumed.121.263323
  • MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of <sup>68</sup>Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
    You have access
    MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
    Leonhard Gruber, Luis David Jiménez-Franco, Clemens Decristoforo, Christian Uprimny, Gerhard Glatting, Peter Hohenberger, Stefan O. Schoenberg, Wolfgang Reindl, Francesca Orlandi, Maurizio Mariani, Werner Jaschke and Irene Virgolini
    Journal of Nuclear Medicine December 1, 2020, 61 (12) 1749-1755; DOI: https://doi.org/10.2967/jnumed.119.238808
  • You have access
    Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer
    Lucia Baratto, Heying Duan, Helmut Mäcke and Andrei Iagaru
    Journal of Nuclear Medicine June 1, 2020, 61 (6) 792-798; DOI: https://doi.org/10.2967/jnumed.119.234971
  • You have access
    Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors
    Clément Morgat, Gaétan MacGrogan, Véronique Brouste, Valérie Vélasco, Nicolas Sévenet, Hervé Bonnefoi, Philippe Fernandez, Marc Debled and Elif Hindié
    Journal of Nuclear Medicine September 1, 2017, 58 (9) 1401-1407; DOI: https://doi.org/10.2967/jnumed.116.188011
  • You have access
    Clinical Translation of a Dual Integrin αvβ3– and Gastrin-Releasing Peptide Receptor–Targeting PET Radiotracer, 68Ga-BBN-RGD
    Jingjing Zhang, Gang Niu, Lixin Lang, Fang Li, Xinrong Fan, Xuefeng Yan, Shaobo Yao, Weigang Yan, Li Huo, Libo Chen, Zhiyuan Li, Zhaohui Zhu and Xiaoyuan Chen
    Journal of Nuclear Medicine February 1, 2017, 58 (2) 228-234; DOI: https://doi.org/10.2967/jnumed.116.177048
  • You have access
    99mTc-Glu-c(RGDyK)-Bombesin SPECT Can Reduce Unnecessary Biopsy of Masses That Are BI-RADS Category 4 on Ultrasonography
    Tiefeng Ji, Shi Gao, Zhaofei Liu, Hua Xing, Guoqing Zhao and Qingjie Ma
    Journal of Nuclear Medicine August 1, 2016, 57 (8) 1196-1200; DOI: https://doi.org/10.2967/jnumed.115.168773
  • You have access
    Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy
    Simone U. Dalm, Anieta M. Sieuwerts, Maxime P. Look, Marleen Melis, Carolien H.M. van Deurzen, John A. Foekens, Marion de Jong and John W.M. Martens
    Journal of Nuclear Medicine October 1, 2015, 56 (10) 1487-1493; DOI: https://doi.org/10.2967/jnumed.115.160739
  • You have access
    In Vivo Cancer Dual-Targeting and Dual-Modality Imaging with Functionalized Quantum Dots
    Kongzhen Hu, Hongliang Wang, Ganghua Tang, Tingting Huang, Xiaolan Tang, Xiang Liang, Shaobo Yao and Dahong Nie
    Journal of Nuclear Medicine August 1, 2015, 56 (8) 1278-1284; DOI: https://doi.org/10.2967/jnumed.115.158873
  • You have access
    Preclinical Comparison of Al18F- and 68Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonists for PET Imaging of Prostate Cancer
    Kristell L.S. Chatalic, Gerben M. Franssen, Wytske M. van Weerden, William J. McBride, Peter Laverman, Erik de Blois, Bouchra Hajjaj, Luc Brunel, David M. Goldenberg, Jean-Alain Fehrentz, Jean Martinez, Otto C. Boerman and Marion de Jong
    Journal of Nuclear Medicine December 1, 2014, 55 (12) 2050-2056; DOI: https://doi.org/10.2967/jnumed.114.141143
  • You have access
    A Comparative Study of Radiolabeled Bombesin Analogs for the PET Imaging of Prostate Cancer
    Yang Liu, Xiang Hu, Hongguang Liu, Lihong Bu, Xiaowei Ma, Kai Cheng, Jinbo Li, Mei Tian, Hong Zhang and Zhen Cheng
    Journal of Nuclear Medicine December 1, 2013, 54 (12) 2132-2138; DOI: https://doi.org/10.2967/jnumed.113.121533
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire